PCI Biotech Holding ASA (OSL:PCIB) EBIT: kr-20.40 Mil (TTM As of Jun. 2025)

What is PCI Biotech Holding ASA EBIT?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 EBIT is kr-20.40 Mil as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2025 was kr-11.44 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was kr-20.40 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PCI Biotech Holding ASA's annualized ROC % for the quarter that ended in Jun. 2025 was -398.30%. PCI Biotech Holding ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -3,935.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PCI Biotech Holding ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 225.58%.

PCI Biotech Holding ASA (OSL:PCIB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PCI Biotech Holding ASA's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

	ROC % (Q: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Jun. 2025 ))	/ count )
=	-23.874 * ( 1 - 0% )	/	( (5.602	+	6.386)	/ 2 )
=	-23.874	/	5.994
=	-398.30 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	31.215	-	2.47	-	( 26.693	-	max(0, 7.762	-	30.905	+	26.693	))
=	5.602

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	18.523	-	0.476	-	( 13.617	-	max(0, 6.008	-	17.669	+	13.617	))
=	6.386

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

PCI Biotech Holding ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Jun. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-22.882	/	( ( (0.308 + max(-6.582, 0))	+	(0.855 + max(-1.674, 0)) )	/	2 )
=	-22.882	/	( ( 0.308	+	0.855 )	/	2 )
=	-22.882	/	0.5815
=	-3,935.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.844)	-	(2.47	+	0	+	4.956)
=	-6.582

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.052	+	0	+	0)	-	(0.476	+	0	+	5.25)
=	-1.674

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PCI Biotech Holding ASA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2025 )
	=	-20.397	/	-9.042
	=	225.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA EBIT Related Terms

PCI Biotech Holding ASA EBIT Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's EBIT can be seen below:

PCI Biotech Holding ASA EBIT Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-71.84

-88.30

-54.97

-20.16

-16.36

PCI Biotech Holding ASA Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
EBIT	Get a 7-Day Free Trial															-11.71	-8.44	-7.37	-8.96	-11.44

OSL:PCIB vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's EV-to-EBIT falls into.

Save Embed

6GF Score

PCI Biotech Holding ASA OSL:PCIB

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PCI Biotech Holding ASA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-20.40 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of kr-20.40 Mil mean?

PCI Biotech Holding ASA (OSL:PCIB) has a EBIT of kr-20.40 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PCI Biotech Holding ASA.

Is PCI Biotech Holding ASA's EBIT too high?

PCI Biotech Holding ASA's current EBIT is kr-20.40 Mil. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.

How does PCI Biotech Holding ASA's EBIT compare to VRTX and REGN?

PCI Biotech Holding ASA's EBIT of kr-20.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PCI Biotech Holding ASA. PCI Biotech Holding ASA's current EBIT is kr-20.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PCI Biotech Holding ASA stock overvalued right now?

PCI Biotech Holding ASA (OSL:PCIB) has a current EBIT of kr-20.40 Mil. The current EBIT is kr-20.40 Mil. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current EBIT is kr-20.40 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Industry Healthcare Biotechnology

Comparable Companies VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL ALNY ONC XKRX:068270 INSM RVMD BNTX RPRX MRNA ROIV HKSE:01801 INCY HKSE:02269 SMMT OCSE:GMAB

Address Ullernchausseen 64, Oslo, NOR, N-0379

Website https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

6GF Score

Get the complete analysis for OSL:PCIB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12

Price

View OSL:PCIB Analysis

See EBIT data for all stocks →